Online citations, reference lists, and bibliographies.
← Back to Search

The Emerging Toxicity Profiles Of Anti-CTLA-4 Antibodies Across Clinical Indications.

A. M. Di Giacomo, M. Biagioli, M. Maio
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The promising new class of immunomodulating antibodies directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4) has been extensively tested in clinical trials and found to be active against cutaneous melanoma and other tumor histotypes. Inhibition of CTLA-4 characteristically induces well-identified side effects for which the definition "immune-related adverse events" (irAEs) has been proposed. IrAEs mainly include colitis/diarrhea, dermatitis, hepatitis, and endocrinopathies; uveitis, nephritis, and inflammatory myopathy also have been reported occasionally. These unique side effects are likely a direct result of breaking immune tolerance upon CTLA-4 blockade and are generally mild, reversible, and manageable, following specific treatment guidelines that include symptomatic therapies or systemic corticosteroids. However, patient-physician communication and early treatment are also emerging as critical issues to successfully manage irAEs, thus avoiding major complications. The major experience in identifying and managing CTLA-4 treatment-related side effects has derived from studies in melanoma patients; nevertheless, accumulating clinical experiences are clearly demonstrating that irAEs are class-specific events, and that they are fully overlapping in patients with tumors of different histotypes. This review provides an overview of current safety data on CTLA-4 antagonists and of available strategies to optimize their clinical use in cancer patients.
This paper references
10.1200/JCO.2010.28.15_SUPPL.8571
Hair depigmentation as an indicator of durable response to CTLA-4 therapy.
A. Pavlick (2010)
10.1056/NEJMe1006416
Treating cancer by targeting the immune system.
P. Hwu (2010)
10.1097/CJI.0b013e318156e47e
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
10.1007/s10620-009-0839-8
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
J. Lord (2009)
10.1158/1078-0432.CCR-06-2318
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
E. Small (2007)
10.1002/cncr.25639
Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
B. Rini (2011)
10.1200/jco.2009.27.15_suppl.8071
Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
P. Zatloukal (2009)
10.1158/1078-0432.CCR-09-2870
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
C. Ralph (2010)
10.1007/s00262-008-0653-8
Ipilimumab: controversies in its development, utility and autoimmune adverse events
J. Weber (2008)
10.1016/j.jaad.2007.07.022
Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody.
J. L. Lim (2008)
10.1097/00002371-200411000-00008
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
M. Robinson (2004)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1097/CJI.0b013e31819aa40b
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
M. Akhtari (2009)
10.1001/ARCHDERM.142.2.166
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
Samer H Jaber (2006)
10.1245/ASO.2005.03.536
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
A. Maker (2005)
10.1634/THEONCOLOGIST.12-7-864
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
J. Weber (2007)
10.1158/1078-0432.CCR-09-1024
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
10.1677/JME.0.0310021
CTLA-4 and its role in autoimmune thyroid disease.
D. Chistiakov (2003)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1200/JCO.2005.06.205
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
10.1007/s11102-009-0193-z
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
T. Dillard (2009)
10.1158/1078-0432.CCR-07-0187
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
10.1056/NEJMc0904283
Anti-CTLA4 antibody-induced lupus nephritis.
F. Fadel (2009)
10.1097/CJI.0b013e318193a206
Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
S. Bhatia (2009)
10.1007/s00262-008-0627-x
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Ilyssa O. Gordon (2008)
10.1200/JCO.2005.04.5716
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Kimberly E. Beck (2006)
10.1158/1078-0432.CCR-10-0505
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
R. Vonderheide (2010)
10.1200/JCO.2010.28.3994
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
K. Chung (2010)
10.1093/annonc/mdq013
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S. O’Day (2010)
10.1200/JCO.2010.28.15_SUPPL.7531
Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
T. Lynch (2010)
10.1200/JCO.2010.28.15_SUPPL.4689
Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC).
A. Harzstark (2010)
10.1017/S0317167100007939
Autoimmune inflammatory myopathy after treatment with ipilimumab.
Gary R W Hunter (2009)
10.1002/cncr.24951
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
G. Ku (2010)
10.1200/JCO.2008.26.15_SUPPL.9063
An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy
R. Lin (2008)



This paper is referenced by
10.1371/journal.pone.0118564
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
L. Zimmer (2015)
10.1007/978-3-319-22539-5_9
Checkpoint Blockade for the Treatment of Advanced Melanoma.
M. Callahan (2016)
10.1016/J.ADENGL.2019.02.017
Adverse Hair Reactions to New Targeted Therapies for Cancer.
Juan Francisco Mir-Bonafé (2019)
10.1097/RLU.0000000000000940
Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.
Yazan Z. Alabed (2015)
10.5772/28125
Chemotherapy–Induced Colitis
C. Barcenas (2012)
10.1378/chest.12-1467
Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
I. Barjaktarevic (2013)
10.5772/23493
Immune-Therapy in Cutaneous Melanoma – Efficacy Immune Markers
M. Neagu (2012)
10.1530/EJE-17-0810
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
E. Scott (2018)
10.1634/theoncologist.2016-0164
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
G. O’Kane (2017)
10.2147/OTT.S57335
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Giuseppina Della Vittoria Scarpati (2014)
10.1016/j.ad.2017.11.021
Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
J. Cervantes (2019)
10.5306/wjco.v5.i2.39
Targeted immunotherapy for non-small cell lung cancer.
M. Vasekar (2014)
Manipulating the immune response of Tasmanian Devils to target Devil Facial Tumour Disease
G. Brown (2013)
10.1038/s41598-019-43068-y
RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4
T. Sekiya (2019)
10.1007/978-3-319-45013-1_27
Drugs and Other Substances Interfering with Thyroid Function
Lucia Montanelli (2018)
10.1172/JCI73340
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
A. Marabelle (2013)
10.21767/2471-8513.100017
Immune checkpoint-targeted therapy: cancer and autoimmune diseases represent two sides of the same coin
N. Isakov (2016)
10.1177/1078155220906885
Sweet’s syndrome under ipilimumab therapy and a brief comparison of the cases in literature
H. A. Yasar (2020)
10.1097/MJT.0b013e3182a39858
Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma
P. Ascierto (2015)
Procédés de traitement d'un cancer positif her2
S. Y. Chui (2016)
10.1073/pnas.1916039117
In situ genetic engineering of tumors for long-lasting and systemic immunotherapy
S. Tzeng (2020)
10.1007/978-3-319-46029-1_60-1
Managing Checkpoint Inhibitor Symptoms and Toxicity
Anna C Pavlick (2019)
Hepatotoxicity induced by PD-1 inhibitors in cancer treatment
(2020)
10.1016/j.bbrc.2013.09.031
A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth.
K. Lan (2013)
10.4172/JPB.1000265
Peptide Vaccine Strategies in the Treatment of Cancer
T. J. Vreeland (2013)
10.12788/jcso.0005
Current options and future directions in the systemic treatment of metastatic melanoma.
Katja A Schindler (2014)
10.5772/50375
Thyroid Function Abnormalities in Patients Receiving Anticancer Agents
F. Torino (2012)
10.1007/s12020-017-1289-2
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab
L. Brilli (2017)
10.1080/01658107.2017.1291686
A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer
William Carrera (2017)
10.1084/jem.20131219
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
M. Bouchlaka (2013)
10.1189/jlb.1212631
At the Bedside: CTLA‐4‐ and PD‐1‐blocking antibodies in cancer immunotherapy
M. Callahan (2013)
10.2217/EBO.11.345
CTLA-4 inhibitors in castration-resistant prostate cancer
Sumit K Subudhi (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar